Alto Neuroscience’s (ANRO) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Alto Neuroscience (NYSE:ANRO) in a report published on Wednesday morning,Benzinga reports. BTIG Research currently has a $37.00 price objective on the stock.

ANRO has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Tuesday, October 27th. HC Wainwright boosted their price objective on Alto Neuroscience from $55.00 to $60.00 and gave the company a “buy” rating in a report on Monday, October 19th. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Wedbush raised their target price on Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Finally, Zacks Research upgraded Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.88.

Alto Neuroscience Trading Down 2.9%

Shares of Alto Neuroscience stock opened at $29.73 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.85 and a current ratio of 18.12. Alto Neuroscience has a 12-month low of $10.80 and a 12-month high of $37.48. The firm’s 50 day simple moving average is $26.38 and its two-hundred day simple moving average is $24.63.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.13. As a group, analysts expect that Alto Neuroscience will post -2.64 earnings per share for the current fiscal year.

Insider Activity at Alto Neuroscience

In other news, CFO Nicholas Smith sold 110,830 shares of the company’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $26.58, for a total value of $2,945,861.40. Following the transaction, the chief financial officer owned 24,060 shares of the company’s stock, valued at $639,514.80. This represents a 82.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 11.25% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors have recently made changes to their positions in ANRO. Commodore Capital LP lifted its holdings in shares of Alto Neuroscience by 49.4% in the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock worth $61,217,000 after acquiring an additional 900,000 shares during the last quarter. Perceptive Advisors LLC raised its position in Alto Neuroscience by 12.6% in the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after purchasing an additional 225,500 shares during the period. Spruce Street Capital LP raised its position in Alto Neuroscience by 494.7% in the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after purchasing an additional 1,102,366 shares during the period. Marshall Wace LLP lifted its stake in Alto Neuroscience by 281.1% during the third quarter. Marshall Wace LLP now owns 859,309 shares of the company’s stock worth $21,938,000 after purchasing an additional 633,806 shares in the last quarter. Finally, Affinity Asset Advisors LLC acquired a new position in Alto Neuroscience during the first quarter worth $11,240,000.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.